Hostname: page-component-cd9895bd7-jn8rn Total loading time: 0 Render date: 2024-12-26T09:33:30.594Z Has data issue: false hasContentIssue false
  • English
  • Français

Curing the Disobedient Patient: Medication Adherence Programs as Pharmaceutical Marketing Tools

Published online by Cambridge University Press:  01 January 2021

Matt Lamkin  and
Carl Elliott
Get access Rights & Permissions [Opens in a new window]

Extract

About a week after Maran Wolston was prescribed Copaxone, a drug for multiple sclerosis (MS), she got a phone call from a nurse at an organization called Shared Solutions. The organization was familiar to Wolston; when her neurologist had asked permission to share her health information with Shared Solutions, Wolston had agreed, assuming it was connected to her health insurance.

The nurse who called Wolston was checking in to see how the treatment was going. It was not going well. While Copaxone is not typically associated with some of the unpleasant side effects of other MS drugs, it does have at least one serious drawback: the drug must be injected every day. The injections can be brutally painful. “No matter where I injected the drug each day, the injection site swelled up into a huge welt and felt like a gigantic bee sting,” Wolston writes.

Type
Symposium
Information
Journal of Law, Medicine & Ethics , Volume 42 , Issue 4 , Winter 2014 , pp. 492 - 500
Copyright
Copyright © American Society of Law, Medicine and Ethics 2014

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Wolston, M., “An MS Patient Loses Trust When She Finds Out Her Doctor Is Paid by Drug Companies,” Health Affairs 30, no. 12(2011): 2449–2452.CrossRefGoogle Scholar
See, e.g., Conrad, P., “The Meaning of Medications: Another Look at Compliance,” Social Science and Medicine 20, no. 1(1985).Holm, S., “What Is Wrong with Compliance?” Journal of Medical Ethics 19, no. 2(1993): 108–110.CrossRefGoogle Scholar
“Understanding and Improving Adherence for Specialty Products,” IMS Health, available at <http://www.imshealth.com/deployedfiles/ims/Global/Content/Solutions/Healthcare%20Analytics%20and%20Services/Specialty%20Analytics/Understanding_Improving_Adherence_Specialty_Products.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Rundall, T.et al, “As Good as It Gets? Chronic Care Management in Nine Leading U.S. Physician Organizations,” BMJ 325 (2002): 958–961.Anderson, G. Knickman, J., “Changing the Chronic Care System to Meet People's Needs,” Health Affairs 20, no. 6(2001): 146–160.CrossRefGoogle Scholar
“Adherence to Long-Term Therapies: Evidence for Action,” World Health Organization, 2003, available at <http://apps.who.int/medicinedocs/en/d/Js4883e/>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Ho, P. M. Magid, D. J. Masoudi, F. A. McClure, D. L. Rumsfeld, J. S., “Adherence to Cardioprotective Medications and Mortality among Patients with Diabetes and Ischemic Heart Disease,” BMC Cardiovascular Disorders 6 (2006): 48.CrossRefGoogle Scholar
Marcum, Z. A. Sevick, M. Handler, S. M., “Medication Nonadherence: A Diagnosable and Treatable Medical Condition,” JAMA 309, no. 20(2013): 2105–2106.CrossRefGoogle Scholar
New England Health Institute, “Thinking Outside the Pillbox: A System-Wide Approach to Improving Patient Medication Adherence for Chronic Disease,” August 2009.Google Scholar
Capgemini Consulting & HealthPrize Technologies, “Annual Pharmaceutical Revenue Loss Due to Medication Non-Adherence,” available at <https://www.adherence564.com/>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Baum, S., “Pharma Patient Adherence Budgets Have Increased 281 Percent in Four Years,” MedCity News, October 12, 2012, available at <http://medcitynews.com/2012/10/pharmapatient-adherence-budgets-have-increased-281-percent-in-four-years/#ixzz2t7sGEyYr>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
McKesson Medication Adherence Programs Achieve New Levels of Patient Adoption and Loyalty, Press Release, June 3, 2010, available at <http://www.mckesson.com/about-mckesson/newsroom/press-releases/2010/mckesson-medication-adherence-programs-achieve-new-levels-of-patient-adoption-and-loyalty/>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Arnold, M., “Thinking Past the Pill,” Medical Marketing & Media, October 2010, available at <http://www.mmm-online.com/patient-marketing-report-thinking-past-the-pill/article/180045/>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Rose, D., “The Reason Why: Smart Packaging Can Improve Habits and Transform Healthcare,” Healthspottr, 5, November 19, 2009.Google Scholar
Id.Google Scholar
Pollack, A., “Take Your Pills, All Your Pills,” New York Times, March 11, 2006.Google Scholar
Frost & Sullivan Whitepaper, Patient Nonadherence: Tools for Combating Persistence and Compliance Issues, available at <http://www.frost.com/prod/servlet/cpo/115071625.pdf%C3%BD>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Harris Interactive, “Oil, Pharmaceutical, Health Insurance, Tobacco, Banking and Utilities Top the List of Industries That People Would Like to See More Regulated,” December 18, 2012, available at <http://www.harrisinteractive.com/News-Room/HarrisPolls/tabid/447/mid/1508/articleId/1131/ctl/ReadCustom%20Default/Default.aspx>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Bertha, B., “The Artful Science of Medication Adherence,” PM360, June 2010.Google Scholar
Id.Google Scholar
Gallup, “Honesty/Ethics in Professions,” December 2013, available at <http://www.gallup.com/poll/1654/honesty-ethics-professions.aspx>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Allen, J. Bell, C., “Nurses: They're Not Just in Hospitals Anymore,” PharmaPhorum, November 27, 2013, available at <http://www.pharmaphorum.com/articles/nurses-theyre-not-just-in-hospitals-anymore>(last visited November 19, 2014).(last visited November 19, 2014).' href=https://scholar.google.com/scholar?q=Allen,+J.+Bell,+C.,+“Nurses:+They're+Not+Just+in+Hospitals+Anymore,”+PharmaPhorum,+November+27,+2013,+available+at+(last+visited+November+19,+2014).>Google Scholar
See Pollack, , supra note 15.Google Scholar
UBC, “Nursing and Adherence,” available at <http://www.ubc.com/services/loyalty/nursing-adherence>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Ad Age Insights White Paper, Pharmaceutical Marketing, October 17, 2011, available at <http://adage.com/images/bin/pdf/WPpharmmarketing_revise.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
See Gallup Honesty/Ethics in Professions Poll, supra note 20.Google Scholar
See Ad Age Insights White Paper, supra note 24.Google Scholar
McKesson Patient Relationship Solutions, “Sponsored Clinical Services,” available at <http://mprsannounce.mckesson.com/MPRS/microsite/sponsored_clinical_services.htm>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
McKesson Patient Relationship Solutions, “Pharmacy Intervention Program,” available at <http://mprsannounce.mckesson.com/MPRS/microsite/pharmacy_intervention_program.htm>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Bertha, B., “The Artful Science of Medication Adherence,” PM360, June 2010.Google Scholar
McKesson Patient Relationship Solutions, available at <http://mprsannounce.mckesson.com/MPRS/microsite/welcome.htm>(last visited November 19, 2014)McKesson Patient Relationship Solutions, “The Future of Medication Adherence,” March 2012.(last+visited+November+19,+2014)McKesson+Patient+Relationship+Solutions,+“The+Future+of+Medication+Adherence,”+March+2012.>Google Scholar
Snow, B., “Magnifying the Authentic Voice of the Patient, DTC Perspectives,” March 2010, available at <http://www.dtcperspectives.com/wp-content/uploads/2011/02/PatientAmbassadors.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Snow, B., “Make Contact,”Pharmaceutical Marketing Europe, January/February 2010.Google Scholar
Snow, B., “Magnifying the Authentic Voice of the Patient,” DTC Perspectives, March 2010, available at <http://www.dtcperspectives.com/wp-content/uploads/2011/02/PatientAmbassa-dors.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Snow & Associates job posting for Advocacy and Recruitment Associate, available at <http://intranet.snow-companies.com/share/jobposting/0000873>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Snow, & Associates, When Executed Effectively and Consistent with FDA Guidelines, Patient Testimonials Continue to Be a Powerful Vehicle for Communicating with Health Consumers Snow: Best Practices 2010, available at <http://snow-companies.com/page/sites/default/files/(5)%20Snow_Regulatory_Position_03_10.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Lamkin, M., “Health Care Reform, Wellness Programs & the Erosion of Informed Consent,” Kentucky Law Journal 101 (2013): 435.Google Scholar
Marcum, Z. A. Sevick, M. Handler, S. M., “Medication Nonadherence: A Diagnosable and Treatable Medical Condition,” JAMA 309, no. 20(2013): 2105–2106.CrossRefGoogle Scholar
Boston Consulting Group, The Hidden Epidemic: Finding a Cure for Unfilled Prescriptions and Missed Doses (2003), available at <http://www.bcg.com/documents/file14265.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Ioannidis, J. P. A., “Contradicted and Initially Stronger Effects in Highly Cited Clinical Research,” JAMA 294, no. 2(2005): 218–228, at 224.CrossRefGoogle Scholar
Giugliano, D. Esposito, K., “Clinical Inertia as a Clinical Safeguard,” JAMA 305 (2011): 1591–1592.CrossRefGoogle Scholar
Garfinkel, D. Mangin, D., “Feasibility Study of a Systematic Approach for Discontinuation of Multiple Medications in Older Adults: Addressing Polypharmacy,” Archives of Internal Medicine 170, no. 18(2010): 1648–1654.CrossRefGoogle Scholar
See Ioannidis, , supra note 39, at 223.CrossRefGoogle Scholar
Id.Google Scholar
Harris, G., “Diabetes Drug Maker Hid Test Data, Files Indicate,” New York Times, July 13, 2010, at A1.Google Scholar
Nissen, S. E. Wolski, K., “Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes,” New England Journal of Medicine 356, no. 24(2007): 2457–2471.CrossRefGoogle Scholar
Harris, G., “F.D.A. to Restrict Avandia, Citing Heart Risk,”New York Times, September 23, 2010, at A1.Google Scholar
Moncrie, J. Cohen, D. Mason, J. P., “The Subjective Experience of Taking Antipsychotic Medication: A Content Analysis of Internet Data,” Acta Psychiatrica Scandinavica 120, no. 2(2009): 102–111.CrossRefGoogle Scholar
Priebe, S. Burton, A.et al, “Financial Incentives to Improve Adherence to Anti-psychotic Maintenance Medication in Non-adherent Patients: A Cluster Randomised Controlled Trial (FIAT),” BMC Psychiatry 9 (2009), available at <http://www.biomedcentral.com/1471–244X/9/61>(last visited November 19, 2014).CrossRefGoogle Scholar
See <http://relationalagents.com/publications/CHI08-mentalhealth.pdf>(last visited November 19, 2014). Bickmore, T. Puskar, K.et al, “Maintaining Reality: Relational Agents for Antipsychotic Medication Adherence,” Interacting with Computers 22, no. 4(2010): 276–288.CrossRefGoogle Scholar
Whitaker, R., Anatomy of an Epidemic: Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America, Broadway Books, 2011.Google Scholar
Lieberman, J. A.et al, “Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia,” New England Journal of Medicine 353, no. 12(2005): 1209–1223.CrossRefGoogle Scholar
Khan, H. Thomas, P., “Drug Giant AstraZeneca to Pay $520 Million to Settle Fraud Case,” ABC News, April 27, 2010, available at <http://abcnews.go.com/Politics/Health/astrazenecapay-520-million-illegally-marketing-seroquel-schizophrenia/story?id=10488647>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
Copaxone Prescribing Information, available at <http://copaxone.com/pdfs/PrescribingInformation.aspx>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
La Mantia, L. Munari, L. M. Lovati, R., “Glatiramer Acetate for Multiple Sclerosis (Review),” The Cochrane Library 5 (2010), available at <http://www.bibliotecacochrane.com/pdf/CD004678.pdf>(last visited November 19, 2014).Google Scholar
Elliott, C., White Coat, Black Hat: Adventures on the Dark Side of Medicine (Boston: Beacon Press, 2010.).Google Scholar
Frost & Sullivan, The Evolution of Patient Adherence Programs: Moving from Mass Market Relationships to a Personal Approach, available at <https://www.frost.com/prod/servlet/cpo/115071626.pdf>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
McKesson Patient Relationship Solutions, The Future of Medication Adherence, March 2012.Google Scholar
Grant, B., “Merck Produced Fake Journal,” The Scientist, April 30, 2009, available at <http://www.the-scientist.com/?articles.view/articleNo/27376/title/Merck-published-fake-journal/>(last visited November 19, 2014).(last+visited+November+19,+2014).>Google Scholar
See Pollack, , supra note 15.Google Scholar